The Evidence Gap the Peptide Industry Doesn’t Want You to Think About
Wellness Peptides: A Consumer’s Guide to What We Know, What We Don’t, and What That Difference Means
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 injectable peptide compounds the FDA had restricted from compounding pharmacies in 2023 are expected to be reclassified moving from the restricted Category 2 list back to Category 1, which means licensed compounding pharmacies could legally prepare and dispense them again under physician prescription. As of this writing, the FDA has not yet published its formal updated list.
Before these compounds reach your pharmacy, you need to understand what the evidence actually shows. Not what the wellness industry says it shows.
A Peptide Is Not a Medicine
Your body produces thousands of peptides that regulate hunger, sleep, immune response, tissue repair, stress, and dozens of other functions.
When the wellness industry markets “peptide therapy,” it is borrowing the credibility of that entire category including, most deliberately, the credibility of two medicines that genuinely transformed metabolic care: insulin, which has been in clinical use for over a century, and semaglutide (Ozempic, Wegovy), which has produced some of the most dramatic obesity and cardiovascular outcomes data in modern medicine.
What made insulin and semaglutide medicines was not their chemistry. For semaglutide, that meant identifying the GLP-1 receptor target, characterizing the pharmacokinetics in humans, running Phase I trials in healthy volunteers to establish safety, then Phase II trials to establish dose-response relationships, then Phase III trials enrolling tens of thousands of patients across multiple independent research programs, measuring hard clinical endpoints, weight, cardiovascular events, mortality, and submitting all of that to independent regulatory review. The SUSTAIN trial program for glycemic control and the SELECT trial for cardiovascular outcomes enrolled over 17,000 patients combined. Independent researchers replicated the findings. The FDA reviewed the complete data package.
The word “peptide” did not make semaglutide a medicine. The evidence did.
The False Equivalence at the Center of the Marketing
The argument made by the wellness peptide industry is this: these compounds are peptides, peptides like semaglutide work, therefore these compounds may work similarly and the regulatory barriers are excessive.
Membership in a molecular category confers nothing about safety or efficacy. The evidentiary hierarchy, from cell culture to animal models to Phase I human safety trials to Phase II to Phase III, exists because history is filled with compounds that healed animals and failed or harmed people. Thalidomide was highly effective in animal models, yet it led to severe birth defects in humans.
Take BPC-157, arguably the most widely marketed of these compounds. According to a 2025 systematic review in HSS Journal, a reputable orthopedic surgery publication, the reviewers examined 544 articles published from 1993 through 2024. They identified 35 preclinical studies and one clinical study: a 12-patient retrospective pain series. The review’s explicit conclusion was that no clinical safety data exists.
Reclassification to Category 1 only changes the legal pathway for access. BPC-157 still has only a handful of published human studies with fewer than 30 total subjects. TB-500 has no completed human randomized controlled trials. The research gaps that existed before the ban still exist after the reclassification.
The Seven Compounds, What the Evidence Actually Shows
BPC-157 is a synthetic fragment of a protein found in gastric juice. It is marketed for tissue healing, gut repair, and injury recovery. The biological mechanism being proposed, promotion of new blood vessel growth, is real and has been characterized in animal studies. But that same mechanism, involving upregulation of VEGFR2 and downstream vascular signaling pathways, is precisely what oncologists target with anti-angiogenic drugs to starve tumors of their blood supply. In a person with an occult or active malignancy, we do not know what BPC-157 does.
TB-500 is a synthetic fragment of thymosin beta-4, marketed for muscle recovery and injury repair. Phase I human safety data does exist for the intact thymosin beta-4 molecule, administered intravenously under pharmaceutical-grade conditions to healthy volunteers in controlled trials. (Ruff et al., Annals of the New York Academy of Sciences, 2010; Wang et al., Journal of Cellular and Molecular Medicine, 2021). The fragment being sold as TB-500 is not the studied molecule. Safety data on a structurally related compound is not safety data for this product.
PT-141 (bremelanotide) an approved version of this compound exists; Vyleesi, a 1.75 mg subcutaneous autoinjector, underwent controlled randomized trials in premenopausal women with acquired generalized hypoactive sexual desire disorder. The trials documented transient blood pressure increases peaking around 12 minutes post-injection, with documented exclusion criteria for cardiovascular risk. Postmenopausal women and men were not part of the studied population. Compounded intranasal bremelanotide formulations are not Vyleesi. They deliver an unknown dose via an unstudied delivery route to an unstudied population, including people with cardiovascular conditions who were specifically excluded from the trials that established the compound’s risk profile.
Selank and Semax are synthetic neuropeptides developed in Russia, where the majority of human research on these compounds originates. A 2020 neuroimaging study at a Russian institution enrolled 52 healthy participants and documented measurable effects on amygdala functional connectivity (Panikratova et al., Doklady Biological Sciences, 2020). That is the largest human study identified for either compound. No independent replication exists. Changes in functional connectivity do not establish clinical efficacy. These compounds have more human data than BPC-157 or TB-500, which is not the same as having adequate human data.
Epithalon is marketed primarily on anti-aging and longevity claims, specifically around telomere lengthening. Telomere shortening is associated with aging, but the biology is not the simple linear equation the marketing implies; correlation between telomere length and chronological age in a 2023 meta-analysis of 743,019 individuals was -0.19, statistically significant but modest (Ye et al., Ageing Research Reviews, 2023). More critically, in cancer biology, telomere lengthening is specifically the mechanism by which malignant cells escape the natural limit on how many times a cell can divide (replicative senescence). A 2025 peer-reviewed study in Biogerontology confirmed that Epithalon activates telomere lengthening in breast cancer cell lines through the ALT mechanism (Al-dulaimi et al., Biogerontology, 2025).
The Manufacturing Problem No One Is Talking About
Even if the evidence for any of these compounds were stronger than it is, a separate and independent problem remains: you are not receiving a pharmaceutical-grade product.
FDA approval of a drug covers far more than the molecule. It covers the dose, the formulation, the manufacturing process, the delivery system, and the studied population. A compounding pharmacy can legally prepare a compound but cannot replicate the level of pharmaceutical manufacturing oversight that accompanied the clinical trials establishing whatever limited evidence exists.
A 2024 analysis of gray-market peptide products found significant variability in actual peptide content versus label claims, contamination with bacterial endotoxins, and in some cases, entirely wrong compounds in the vial.
Industry sources and proponents of these compounds have themselves acknowledged that much of the active pharmaceutical ingredient used in compounding originates from Chinese chemical manufacturers operating outside Good Manufacturing Practice (GMP) oversight. The quality depends entirely on a chain of custody that no regulatory body is monitoring.
Several of these compounds are sold in nasal spray form — Semax, Selank, and PT-141 variants appear most commonly in this format. The nasal mucosa presents three overlapping barriers to peptide absorption: enzymatic degradation by peptidases and proteases present in nasal secretions, tight junction barriers in the mucosal epithelium, and mucociliary clearance that physically removes deposited material before it can be absorbed.
Novo Nordisk, Pfizer, and other major pharmaceutical companies with dedicated formulation science divisions invested decades of resources and serious scientific effort in intranasal insulin delivery. They could not make it work reliably. Studies found intranasal doses requiring approximately 20 times higher than subcutaneous doses, with bioavailability of 16–20% at best and high inter-individual variability (Hilsted et al., Diabetologia, 1995; Leary et al., Diabetes Technology and Therapeutics, 2006). A 2024 adaptive dose-escalation study administered up to 1,000 units intranasally and still found idiosyncratic absorption with two hypoglycemic episodes at 600 units, unpredictable even at extreme doses (Schmitzberger et al., Clinical and Translational Science, 2024).
No intranasal insulin formulation to date has received regulatory approval for metabolic use. A compounding pharmacy dissolving a peptide in saline and filling a nasal spray bottle has not solved what industrial pharmaceutical science could not.
How to Think About This
The February 2026 announcement signals that some of these compounds will soon be accessible through legitimate pharmacy channels rather than gray-market chemical suppliers. That is a meaningful improvement in quality control for people who are going to use them regardless of what the evidence shows.
If a wellness practitioner or compounding pharmacy is currently offering you these compounds, here are the questions worth asking before you agree:
What is the specific mechanism of action, and what human data supports it? Not animal data. Human data — Phase I or II trials, with sample sizes, published in peer-reviewed journals. If the practitioner cannot name specific studies with human subjects, you have your answer.
What adverse effects were documented in the studied population, and am I in a group that was excluded from those studies? PT-141’s cardiovascular effects in people with cardiac risk factors are undefined. BPC-157’s behavior in someone with occult malignancy is unknown.
Where was the active ingredient manufactured, and what quality certification applies to that facility? GMP certification from an FDA-recognized facility is the minimum standard. “Research use only” material is, by definition, not manufactured to human-use quality standards.
If something goes wrong, who is monitoring for it, who do I report it to, and what accountability structure exists? The answer under the current system, even post-reclassification, is: essentially none.
The evidence does not currently support use of most of these compounds outside of properly designed clinical trials. Several of these compounds present genuinely interesting biological hypotheses, and some may eventually earn clinical validation through the pathway that semaglutide and insulin traveled. But the possibility of future evidence is not the same as current evidence.
If you are being offered these compounds today, you are not participating in cutting-edge medicine. You are paying to be an unmonitored subject in an uncontrolled experiment with no follow-up and no data collection.
Found this article useful? Share your thoughts — Join the conversation below.
Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value in it and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.
The Metabolic Archives is for educational and informational purposes only, and is not intended as medical advice, diagnosis, or treatment, and does not constitute a doctor-patient relationship. Do not adopt any recommendation discussed in any article or guides published here, make changes or abandon any prescribed medical treatment without prior consultation with your physician. Always seek the advice of your physician or other qualified health provider for any questions regarding your medical condition and recommended treatment options.
By reading this post, you acknowledge that you have read and agree to the Terms of Service of The Metabolic Archives, which govern all use of this content including restrictions on reproduction.
© 2026 The Metabolic Archives. All rights reserved.